3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)-benzyl phosphonic acid,diethyl ester | 219691-98-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)-benzyl phosphonic acid,diethyl ester
• 英文别名: diethyl [3,5-dibromo-4-(4'-hydroxy-3'-iso-propylphenoxy)]benzylphosphonate；3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzyl phosphonic acid, diethyl ester；4-[2,6-dibromo-4-(diethoxyphosphorylmethyl)phenoxy]-2-propan-2-ylphenol
• CAS: 219691-98-2
• 化学式: C₂₀H₂₅Br₂O₅P
• 分子量: 536.197
• InChiKey: XNDYHAOVEWYMNF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  28
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  65
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)-benzyl phosphonic acid,diethyl ester 在 water ethanol 作用下， 以 盐酸 为溶剂， 反应 24.0h， 以to give 10 mg (0.021 mmol, 53%) of 3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)-benzylphosphonic acid as white crystalls的产率得到[3,5-dibromo-4-(4'-hydroxy-3'-isopropylphenoxy)]benzylphosphonic acid
  参考文献：
  名称：

  Thyroid receptor ligands and method

  摘要：

  本发明提供了一种具有通式（I）的新型甲状腺受体配体，其中R1是1至4个碳的烷基或3至7个碳的环烷基；R2和R3相同或不同，可以是氢、卤素、1至3个碳的烷基或3至5个碳的环烷基，其中至少一个不是氢；n是0至4的整数；R4是脂肪烃、芳香烃、其羧酸酯、烯丙基羧酸或其酯、羟基、卤素、氰基、磷酸或其酯，或其药学上可接受的盐。本发明还提供了一种治疗与代谢功能障碍或依赖于T3调节基因表达的疾病，如肥胖症、高胆固醇血症、骨质疏松症、甲状腺功能减退症和甲状腺肿的方法。

  公开号：

  US06465687B1
• 作为产物：
  描述：

  3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzylbromide 在 亚磷酸三乙酯 作用下， 以 乙酸乙酯 、 甲苯 、 Petroleum ether 为溶剂， 以308 mg (0.577 mmol, 56%)的产率得到3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)-benzyl phosphonic acid,diethyl ester
  参考文献：
  名称：

  Thyroid receptor ligands and method

  摘要：

  提供了具有一般式(I)的新型甲状腺受体配体 其中R1是1至4个碳原子的烷基或3至7个碳原子的环烷基；R2和R3相同或不同，是氢、卤素、1至3个碳原子的烷基或3至5个碳原子的环烷基，R2和R3中至少有一个不是氢；n是从0到4的整数；R4是脂肪烃、芳香烃、羧酸酯、烯基羧酸或其酯、羟基、卤素、氰基、磷酸或其酯，或其药用可接受盐。还提供了一种治疗与代谢功能障碍或依赖T3调节基因表达的疾病有关的方法，如肥胖症、高胆固醇血症、骨质疏松症、甲状腺功能减退症和甲状腺肿。

  公开号：

  US06465687B1

文献信息

• Novel Phosphinic Acid-Containing Thyromimetics
  申请人：Erion Mark D.

  公开号：US20090028925A1

  公开（公告）日：2009-01-29

  The present invention relates to compounds of phosphonic acid-containing T3 mimetics and monoesters thereof, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome x and diabetes.

  本发明涉及含有磷酸基T3拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟
• Novel Phosphorus-Containing Thyromimetics
  申请人：Erion Mark D.

  公开号：US20100081634A1

  公开（公告）日：2010-04-01

  The present invention relates to compounds of phosphonic acid-containing T3 mimetics and monoesters thereof, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome x and diabetes.

  本发明涉及含有膦酸的T3模拟物化合物及其单酯、立体异构体、药学上可接受的盐、共晶体和前药及其药学上可接受的盐和共晶体，以及它们的制备和用于预防和/或治疗代谢性疾病，如肥胖症、NASH、高胆固醇血症和高脂血症，以及相关疾病，如动脉粥样硬化、冠心病、糖耐量受损、代谢综合征X和糖尿病的用途。
• NOVEL THYROID RECEPTOR LIGANDS AND METHOD
  申请人：KARO BIO AB

  公开号：EP1000008B1

  公开（公告）日：2003-06-25
• Thyromimetics for the Treatment of Fatty Liver Diseases
  申请人：Cable Edward E.

  公开号：US20090232879A1

  公开（公告）日：2009-09-17

  The present invention is directed toward the use of thyromimetic compounds that are thyroid receptor ligands, pharmaceutically acceptable salts thereof, and to prodrugs of these compounds for preventing, treating, or ameliorating fatty liver diseases such as steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.
• METHOD OF REDUCING THYROID-ASSOCIATED SIDE EFFECTS
  申请人：Viking Therapeutics, Inc.

  公开号：US20190255080A1

  公开（公告）日：2019-08-22

  The present disclosure is directed to methods of administration of thyroid hormone receptor agonists. The disclosure provides methods wherein the activity of the given thyroid receptor agonists in ameliorating or curing obesity, hyperlipidemia, hypercholesterolemia, diabetes, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, hypothyroidism, and related disorders is maintained, while thyroid-related and thyroid axis-related side effects are reduced or eliminated.